VNLG 152
Alternative Names: HT 003D; HT 003IBD; HT-003; VNLG -152Latest Information Update: 13 Aug 2025
At a glance
- Originator Isoprene Pharmaceuticals; University of Maryland, Baltimore
- Developer Hoth Therapeutics; University of Maryland, Baltimore; Weill Cornell Medicine
- Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
- Mechanism of Action Retinoic acid metabolism inhibitors; Toll-like receptor 2 antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acne; Psoriasis
- Research Inflammatory bowel diseases
- No development reported Cancer